Details
Positive Phase 3 Results for ATTR-CM
AstraZeneca has reported positive Phase 3 clinical trial results for Wainua in transthyretin amyloid cardiomyopathy (ATTR-CM).
The findings represent another important milestone in advancing treatment options for patients with rare cardiovascular diseases.